Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Recommendation of “Buy” from Brokerages

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) has been assigned an average recommendation of “Buy” from the thirteen ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, ten have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $39.80.

A number of equities research analysts have weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 21st. Chardan Capital reissued a “buy” rating and issued a $30.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, January 2nd. Piper Sandler restated an “overweight” rating on shares of Centessa Pharmaceuticals in a research note on Friday, January 16th. Truist Financial raised their price objective on Centessa Pharmaceuticals from $33.00 to $38.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. Finally, B. Riley Financial boosted their target price on Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a “buy” rating in a report on Monday, December 1st.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 73,196 shares of the firm’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the completion of the sale, the insider directly owned 65,925 shares in the company, valued at approximately $1,735,805.25. This trade represents a 52.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Iqbal J. Hussain sold 38,951 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $25.15, for a total transaction of $979,617.65. Following the completion of the transaction, the insider directly owned 57,645 shares of the company’s stock, valued at $1,449,771.75. This trade represents a 40.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 307,997 shares of company stock valued at $8,192,203 in the last quarter. 7.09% of the stock is owned by insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. American Century Companies Inc. lifted its position in Centessa Pharmaceuticals by 3.5% in the 2nd quarter. American Century Companies Inc. now owns 1,130,708 shares of the company’s stock valued at $14,858,000 after acquiring an additional 37,954 shares in the last quarter. Eagle Health Investments LP bought a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter worth $2,500,000. Royce & Associates LP bought a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter worth $5,999,000. Federated Hermes Inc. purchased a new position in shares of Centessa Pharmaceuticals in the third quarter worth $42,429,000. Finally, Avoro Capital Advisors LLC lifted its holdings in shares of Centessa Pharmaceuticals by 116.2% during the third quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock valued at $262,096,000 after purchasing an additional 5,808,080 shares in the last quarter. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Down 4.5%

NASDAQ:CNTA opened at $27.06 on Monday. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57. The firm’s 50-day moving average price is $25.26 and its 200-day moving average price is $24.75. The company has a market capitalization of $3.95 billion, a PE ratio of -14.79 and a beta of 1.54. Centessa Pharmaceuticals has a 1-year low of $9.60 and a 1-year high of $30.58.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.